ProtoKinetix

ProtoKinetix Current Liabilities

Current Liabilities of ProtoKinetix (PKTX) as of Nov 19, 2026.

Current Liabilities

0.00USD

Last updated:

Current Liabilities of ProtoKinetix is 2025 0.00 USD. Current Liabilities of ProtoKinetix was 2024 - USD. It decreases by % lower compared to the previous year.

The ProtoKinetix Current Liabilities history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Current Liabilities
Date
Current Liabilities
Jan 1, 2015
45,388.00 USD
Jan 1, 2017
171,468.00 USD
Jan 1, 2019
25,519.52 USD
Jan 1, 2020
44,958.96 USD
Jan 1, 2021
93,267.27 USD
Jan 1, 2022
41,529.53 USD
Jan 1, 2023
44,695.70 USD
Jan 1, 2025
0.00 USD
The ProtoKinetix Current Liabilities history
YEARCurrent LiabilitiesYoY
0.00USD-100.00%
44,695.70USD+7.62%
41,529.53USD-55.47%
93,267.27USD+107.45%
44,958.96USD+76.17%
25,519.52USD-85.12%
171,468.00USD+277.78%
45,388.00USD-91.10%
510,000.00USD+2.69%
496,654.00USD+19.76%
414,701.00USD+207,250.50%
200.00USD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

ProtoKinetix Stock analysis

What does ProtoKinetix do? ProtoKinetix Inc. is a Canadian biotechnology company focused on the development of glycoproteins for therapeutic applications. The company was founded in 2005 and is headquartered in Marietta, USA. ProtoKinetix specializes in the research and development of AAGP® (Anti-Aging Glycopeptide) as biopharmaceuticals. These proprietary glycoproteins have the ability to protect cells and can be used in various therapeutic applications for improving damage in physical injury, spinal cord injury, diabetes, transplantation, and retinal diseases. In addition to the medical field, ProtoKinetix is also developing its patented technology for use in bio-agriculture and animal healthcare. It has a subsidiary that holds the rights to use and distribute AAGP® and its patents. ProtoKinetix's business model involves licensing its glycoprotein technology for various applications, including biopharmaceuticals, bioprocessing industries, and cell protection management for regenerative medicine and stem cell preparations. The company has established partnerships with other biotech companies to integrate its AAGP® technology into their product pipelines. ProtoKinetix's flagship product is the AAGP® protein solution, which is used as a medication in regenerative medicine, organ transplantation, eye healing, and animal health. It is also interested in researching the application of AAGP® in crop farming to increase yields and improve soil quality. ProtoKinetix is poised to play a significant role in the development of glycoproteins as future medicines and therapeutic technologies in various industries. It not only has the potential to explore healing medical products but also aims to enhance agriculture and animal care. ProtoKinetix represents an excellent example of a biotechnology company focused on improving the healthcare and agricultural industries. ProtoKinetix is one of the most popular companies on Eulerpool.

Frequently Asked Questions about ProtoKinetix stock

On Eulerpool you can find the complete historical development of Current Liabilities ProtoKinetix since 2006 – with annual values, charts, and detailed analysis.

Current liabilities are obligations due within one year, including accounts payable, short-term debt, and accrued expenses.

Current Liabilities's USD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Current Liabilities's ProtoKinetix historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Balance Sheet — ProtoKinetix

All Key Metrics — ProtoKinetix